Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

por Remmerie, Bart, De Meulder, Marc, Weiner, Sveta, Savitz, Adam
Publicado 2016

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

por Remmerie, Bart, De Meulder, Marc, Ariyawansa, Jay, Savitz, Adam
Publicado 2016

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population

por Russu, Alberto, Mathews, Maju, Savitz, Adam, Gopal, Srihari, Feng, Yu
Publicado 2016

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

por Gopal, Srihari, Liu, Yanning, Alphs, Larry, Savitz, Adam, Nuamah, Isaac, Hough, David
Publicado 2013

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

por Nash, Abigail I, Turkoz, Ibrahim, Savitz, Adam J, Mathews, Maju, Kim, Edward
Publicado 2019

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()

por Pandina, Gahan, Nuamah, Isaac, Petersen, Timothy, Singh, Jaskaran, Savitz, Adam, Hough, David
Publicado 2020

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, doub...

por Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Mathews, Maju, Soares, Bernardo
Publicado 2019

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophreni...

por Mathews, Maju, Nuamah, Isaac, Savitz, Adam, Hough, David, Najarian, Dean, Kim, Edward, Gopal, Srihari
Publicado 2016

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia

por Savitz, Adam, Haiyan, Xu, Gopal, Srihari, Nuamah, Isaac, Hough, David, Mathews, Maju, Feng, Yu
Publicado 2016

Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study

por Kane, John M., Correll, Christoph U., Delva, Nicholas, Gopal, Srihari, Savitz, Adam, Mathews, Maju
Publicado 2019

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

por Gopal, Srihari, Xu, Haiyan, McQuarrie, Kelly, Savitz, Adam, Nuamah, Isaac, Woodruff, Kimberly, Mathews, Maju
Publicado 2017

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

por Savitz, Adam J, Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Hough, David, Hargarter, Ludger
Publicado 2019

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

por Mathews, Maju, Pei, Huiling, Savitz, Adam, Nuamah, Isaac, Elefant, Erica, Hough, David, Alphs, Larry, Gopal, Srihari
Publicado 2016

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

por Mathews, Maju, Nuamah, Isaac, Savitz, Adam J, Hough, David W, Najarian, Dean, Kim, Edward, Gopal, Srihari
Publicado 2018

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study

por Savitz, Adam, Wajs, Ewa, Zhang, Yun, Xu, Haiyan, Etropolski, Mila, Thase, Michael E, Drevets, Wayne C
Publicado 2021

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate

por Elefant, Erica, Sliwa, Jennifer Kern, Savitz, Adam, Nuamah, Isaac, Mathews, Maju, Gopal, Srihari, Najarian, Dean, Alphs, Larry
Publicado 2016

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

por Mathews, Maju, Gopal, Srihari, Singh, Arun, Nuamah, Isaac, Pungor, Katalin, Tan, Wilson, Soares, Bernardo, Kim, Edward, Savitz, Adam J
Publicado 2020

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

por Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Janik, Adam, Schotte, Alain, Hough, David, Fleischhacker, Wolfgang W.
Publicado 2016

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

por Mathews, Maju, Gopal, Srihari, Nuamah, Isaac, Hargarter, Ludger, Savitz, Adam J, Kim, Edward, Tan, Wilson, Soares, Bernardo, Correll, Christoph U
Publicado 2019

Genome-wide association study of paliperidone efficacy

por Li, Qingqin, Wineinger, Nathan E., Fu, Dong-Jing, Libiger, Ondrej, Alphs, Larry, Savitz, Adam, Gopal, Srihari, Cohen, Nadine, Schork, Nicholas J.
Publicado 2017